Bayer AG has expanded its oncology portfolio with the acquisition of Vividion Therapeutics Inc of the US and its proprietary drug discovery platform. Vividion’s technology involves identifying previously unknown pockets on well-validated protein targets implicated in a wide range of diseases. The company’s lead programmes are small molecule drugs targeting NRF2 mutant cancers as well as NRF2 activators for a number of inflammatory diseases. NRF2 is a protein that helps regulate the work of antioxidant proteins that protect against oxidative damage.
